YungShin Global Holding Corporation's animal health subsidiary, Vetnostrum Animal Health, is expected to go public in the first quarter of next year. The management has indicated that future growth will continue through mergers and acquisitions or investments, focusing on three key areas: new businesses, new markets, and new products/technologies. An important upcoming task is to explore the merger of health supplements and active pharmaceutical ingredients (APIs) as they advance toward the capital markets. The company is also targeting 15 sub-industries for investment, including areas such as cell therapy, upstream protein production, and AI.
Vetnostrum has recently passed the review by the stock exchange and anticipates listing in the first quarter of next year. The company previously acquired Pfizer's Hsinchu plant, merging it with YungShin's animal drug division, which was established as Vetnostrum in 2016. It is the only animal pharmaceutical manufacturer in Taiwan with international high standards, featuring production lines for both standard and high-potency sterile injectable antibiotics. The company aims to develop a value chain through vertical integration, maximizing industry value and streamlining the process from production to sales. Recently, they have also been in talks with original research manufacturers for contract manufacturing.
Management recently stated that besides Vetnostrum's prior acquisition of the animal drug division and its push into capital markets, the group is now considering the merger of health supplements and APIs as the next significant step. They plan to continue pursuing mergers related to APIs, health supplements, and pharmaceuticals, with a focus on the U.S. and Taiwan as priority markets.
Future external expansions will focus on new businesses, new markets, and new products/technologies. They have invested in Japanese glycoengineering to acquire the manufacturing and technology for glycosylated pharmaceuticals and have a new drug project expected to reveal results in the third quarter. In the fields of AI, biopharmaceuticals, and cell therapy, they have already allied with Acer Medical to promote the AI-assisted diagnostic tool VeriSee DR for diabetic retinopathy, aiming to expand into the medical diagnostics sector. For biopharmaceuticals and cell therapy, they are currently discussing collaborations with several partners and are eager to develop these three areas, while large-scale mergers are being assessed cautiously.
Currently, their merger direction prioritizes ongoing evaluations of existing business-related targets, with several projects in progress aimed at creating synergies that can be integrated into their business portfolio. The second part focuses on investments, with the group targeting 15 sub-industries, some of which are currently underserved, such as cell therapy, upstream protein production, and AI. They are open to investing in external entities without seeking control, aiming to learn and enter new fields.
Resource (mandarin): 永信下階段擴張鎖定保健品和原料藥，旗下永鴻生技明年Q1上市
